NASDAQ:AGTC

Applied Genetic Technologies Stock Forecast, Price & News

$4.03

-0.03 (-0.74 %)

(As of 04/13/2021 11:15 AM ET)

Add

Compare

Today's Range

$3.98

Now: $4.03▼

$4.12

50-Day Range

$4.41

MA: $5.26▼

$7.03

52-Week Range

$3.56

Now: $4.03▼

$9.67

Volume16,708 shs

Average Volume2.99 million shs

Market Capitalization$172.29 million

P/E RatioN/A

Dividend YieldN/A

Beta2.33

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AGTC

Previous Symbol

CUSIPN/A

CIK1273636

Webwww.agtc.com

Phone386-462-2204

Employees83

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.17

Current Ratio5.27

Quick Ratio5.27

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.45 million

Price / Sales70.32

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.76 per share

Price / Book1.46

Profitability

EPS (Most Recent Fiscal Year)($2.17)

Net Income$-45,890,000.00

Net MarginsN/A

Return on Equity-73.06%

Return on Assets-53.25%

Miscellaneous

Outstanding Shares42,752,000

Market Cap$172.29 million

Next Earnings Date5/12/2021 (Estimated)

OptionableOptionable

Headlines

TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
April 13, 2021 | finance.yahoo.com

Are Institutions Heavily Invested In Applied Genetic Technologies Corporation's (NASDAQ:AGTC) Shares?
April 7, 2021 | nasdaq.com

Applied Genetic Technologies Co. (NASDAQ:AGTC) Receives Consensus Recommendation of "Buy" from Analysts
April 5, 2021 | americanbankingnews.com

AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
March 31, 2021 | finance.yahoo.com

AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
March 25, 2021 | finance.yahoo.com

AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
March 18, 2021 | finance.yahoo.com

AGTC to Present at Upcoming Investor Conferences
March 2, 2021 | finance.yahoo.com

AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
February 16, 2021 | finance.yahoo.com

AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
February 16, 2021 | finance.yahoo.com

Applied Genetic Technologies Corp. to Host Earnings Call
February 11, 2021 | finance.yahoo.com

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
February 11, 2021 | finance.yahoo.com

AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
February 4, 2021 | finance.yahoo.com

AGTC Announces Pricing of Public Offering of Common Stock and Warrants
January 28, 2021 | finance.yahoo.com

AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
January 27, 2021 | finance.yahoo.com

AGTC Announces Proposed Public Offering of Common Stock and Warrants
January 27, 2021 | finance.yahoo.com

Applied Genetic Technologies' (NASDAQ:AGTC) Stock Price Has Reduced 68% In The Past Five Years
January 25, 2021 | finance.yahoo.com

Applied Genetic Technologies
January 22, 2021 | fool.com

Applied Genetic Technologies Corp/DE
January 22, 2021 | bloomberg.com

Is AGTC A Good Stock To Buy Now?
December 11, 2020 | finance.yahoo.com

Why Applied Genetic Technologies' (NASDAQ:AGTC) CEO Pay Matters
December 11, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.47 out of 5 stars

Medical Sector

560th out of 2,016 stocks

Biological Products, Except Diagnostic Industry

80th out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Applied Genetic Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.58, Applied Genetic Technologies has a forecasted upside of 338.5% from its current price of $4.01.
Amount of Analyst Coverage
Applied Genetic Technologies has only been the subject of 3 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Applied Genetic Technologies has received 420 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Applied Genetic Technologies has received 272 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Applied Genetic Technologies has received 60.69% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote “Outperform” if you believe AGTC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Applied Genetic Technologies does not currently pay a dividend.
Dividend Growth
Applied Genetic Technologies does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Genetic Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Applied Genetic Technologies is held by insiders.
Percentage Held by Institutions
57.88% of the stock of Applied Genetic Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Applied Genetic Technologies are expected to decrease in the coming year, from ($2.11) to ($2.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Genetic Technologies is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Genetic Technologies is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Applied Genetic Technologies has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$4.03

-0.03 (-0.74 %)

(As of 04/13/2021 11:15 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter.

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

Is Applied Genetic Technologies a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Applied Genetic Technologies stock.
View analyst ratings for Applied Genetic Technologies or view top-rated stocks.

What stocks does MarketBeat like better than Applied Genetic Technologies?

Wall Street analysts have given Applied Genetic Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Applied Genetic Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Applied Genetic Technologies?

Applied Genetic Technologies saw a increase in short interest in February. As of February 26th, there was short interest totaling 2,360,000 shares, an increase of 44.8% from the February 11th total of 1,630,000 shares. Based on an average daily trading volume, of 2,690,000 shares, the days-to-cover ratio is presently 0.9 days.
View Applied Genetic Technologies' Short Interest.

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for Applied Genetic Technologies.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings results on Wednesday, February, 10th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.01.
View Applied Genetic Technologies' earnings history.

How has Applied Genetic Technologies' stock price been impacted by COVID-19?

Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGTC shares have increased by 4.9% and is now trading at $4.03.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AGTC?

6 brokers have issued 1 year price targets for Applied Genetic Technologies' shares. Their forecasts range from $7.50 to $35.00. On average, they anticipate Applied Genetic Technologies' share price to reach $17.58 in the next twelve months. This suggests a possible upside of 336.3% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies or view top-rated stocks among Wall Street analysts.

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the following people:

Ms. Susan B. Washer, Pres, CEO & Director (Age 60, Pay $795.26k)
Dr. Mark S. Shearman, Chief Scientific Officer (Age 61, Pay $613.92k)
Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 65, Pay $486.77k)
Dr. Matthew Feinsod, Exec. VP of Global Strategy & Devel. (Age 50, Pay $549.67k)
Dr. Nicholas Muzyczka, Co-Founder
Dr. Barry J. Byrne, Co-Founder
Dr. William W. Hauswirth, Co-Founder & Member of Ophthalmology Scientific Advisory Board
Dr. Richard Jude Samulski, Co-Founder
Dr. Terence R. Flotte, Co-Founder
Mr. William A. Sullivan, Chief Financial Officer (Age 50)

Who are some of Applied Genetic Technologies' key competitors?

Some companies that are related to Applied Genetic Technologies include Harpoon Therapeutics (HARP), Osiris Therapeutics (OSIR), CEL-SCI (CVM), DBV Technologies (DBVT), Athira Pharma (ATHA), Vaxart (VXRT), Tarsus Pharmaceuticals (TARS), MeiraGTx (MGTX), Compugen (CGEN), Agenus (AGEN), Oyster Point Pharma (OYST), Poseida Therapeutics (PSTX), Solid Biosciences (SLDB), Precision BioSciences (DTIL) and AVROBIO (AVRO).
View all of AGTC's competitors.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $4.03.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies has a market capitalization of $172.29 million and generates $2.45 million in revenue each year. The biotechnology company earns $-45,890,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Applied Genetic Technologies have?

Applied Genetic Technologies employs 83 workers across the globe.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is www.agtc.com.

Where are Applied Genetic Technologies' headquarters?

Applied Genetic Technologies is headquartered at 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here